Skip to main content

Table 2 NF-κB staining by patient and tumor characteristics, the VUMC TROC

From: Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis

Characteristic N % * p52 (Non-canonical NF-κB transcription factor) p65 (Canonical NF-κB transcription factor)
Cytoplasmic Nuclear Cytoplasmic Nuclear
Median P-value ** Median P-value ** Median P-value ** Median P-value **
Race
 White 180 (91.8) 135.9 0.698 1.0 0.815 156.1 0.956 2.7 0.831
 Black, other, & unknown 16 (8.2) 122.8   1.0   144.0   2.4  
Stage of disease a
 Early (I/II) 58 (29.6) 81.0 < 0.001 0.0 < 0.001 135.0 0.065 1.8 0.133
 Late (III/IV) 137 (69.9) 164.8   1.8   158.6   3.0  
Histologic subtype
 Serous 143 (72.9) 152.0 < 0.001 2.2 < 0.001 165.4 < 0.001 3.9 < 0.001
 Endometrioid & clear cell 35 (17.9) 97.7   0.0   118.8   0.4  
 Mucinous & others 18 (9.2) 12.1   0.0   122.8   1.4  
Grade - all cases
 Borderline 19 (9.7) 38.3 < 0.001 0.0 0.005 123.4 0.017 1.6 0.002
 Low-grade 33 (16.8) 103.6   0.4   127.4   0.0  
 High-grade 144 (73.5) 157.8   1.6   160.0   3.9  
Grade - invasive serous
 Low-grade serous 13 (7.5) 117.2 0.057 1.0 0.237 146.0 0.027 1.4 0.034
 High-grade serous 118 (67.8) 165.8   3.2   168.1   4.2  
Residual disease b
 Optimal 60 (53.1) 121.4 0.102 1.6 0.723 157.3 0.970 2.6 0.191
 Suboptimal 53 (46.9) 168.7   1.7   158.6   3.8  
Chemotherapy
 Platinum and/or taxane 152 (77.6) 152.0 0.002 1.6 0.010 156.5 0.090 2.8 0.145
 None or unknown 44 (22.4) 91.4   0.0   144.7   1.8  
Response to platinum c
 Platinum sensitive 105 (77.7) 152.0 0.538 1.6 0.558 161.4 0.771 2.8 0.808
 Resistant or refractory 30 (22.2) 142.8   1.0   146.5   3.8  
  1. * Column percentages may not sum to 100% due to rounding error
  2. ** Bold values denote significant differences by the Kruskal-Wallis test; those in italics denote that significance surpasses a Bonferroni corrected threshold for multiple comparisons (P-value ≤ 0.003571)
  3. a Excluding one case with unstaged disease
  4. b Among cases who had debulking surgery and outcomes ascertained
  5. c Among patients who had dates of first-line platinum chemotherapy available
\